Dublin, Feb. 19, 2020 (GLOBE NEWSWIRE) -- The "Attention-Deficit/Hyperactivity Disorder (ADHD) Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
Attention-Deficit/Hyperactivity Disorder (ADHD) Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Attention-deficit/hyperactivity disorder (ADHD) market.
A detailed picture of the Attention-deficit/hyperactivity disorder (ADHD) pipeline landscape is provided, which includes the disease overview and Attention-deficit/hyperactivity disorder (ADHD) treatment guidelines. The assessment part of the report embraces in-depth Attention-deficit/hyperactivity disorder (ADHD) commercial assessment and clinical assessment of the Attention-deficit/hyperactivity disorder (ADHD) pipeline products from the pre-clinical developmental phase to the marketed phase.
In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Attention-deficit/hyperactivity disorder (ADHD) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
The report provides insights into:
- All of the companies that are developing therapies for the treatment of Attention-deficit/hyperactivity disorder (ADHD) with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Attention-deficit/hyperactivity disorder (ADHD) treatment.
- Attention-deficit/hyperactivity disorder (ADHD) key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Attention-deficit/hyperactivity disorder (ADHD) market.
Scope of the Report
- The Attention-deficit/hyperactivity disorder (ADHD) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Attention-deficit/hyperactivity disorder (ADHD) across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Attention-deficit/hyperactivity disorder (ADHD) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.
- Detailed Attention-deficit/hyperactivity disorder (ADHD) research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Attention-deficit/hyperactivity disorder (ADHD).
Key Questions
- What are the current options for Attention-deficit/hyperactivity disorder (ADHD) treatment?
- How many companies are developing therapies for the treatment of Attention-deficit/hyperactivity disorder (ADHD)?
- What are the principal therapies developed by these companies in the industry?
- How many therapies are developed by each company for the treatment of Attention-deficit/hyperactivity disorder (ADHD)?
- How many Attention-deficit/hyperactivity disorder (ADHD) emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Attention-deficit/hyperactivity disorder (ADHD)?
- Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Attention-deficit/hyperactivity disorder (ADHD) market?
- Which are the dormant and discontinued products and the reasons for the same?
- What is the unmet need for current therapies for the treatment of Attention-deficit/hyperactivity disorder (ADHD)?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Attention-deficit/hyperactivity disorder (ADHD) therapies?
- What are the clinical studies going on for Attention-deficit/hyperactivity disorder (ADHD) and their status?
- What are the results of the clinical studies and their safety and efficacy?
- What are the key designations that have been granted for the emerging therapies for Attention-deficit/hyperactivity disorder (ADHD)?
- How many patents are granted and pending for the emerging therapies for the treatment of Attention-deficit/hyperactivity disorder (ADHD)?
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/wrs4dx
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.